FibroGen, Inc. of San Francisco has received SFDA approval to begin China clinical trials of FG-4592, a novel investigational oral therapy for anemia patients with chronic kidney disease. The SFDA approved protocols for Phase I and II tests of the drug through the Green Channel process. The SFDA accepted the filing in November 2009, and the Phase I trial will begin before the end of 2010. More details....